{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:01:29Z","timestamp":1787806889351,"version":"build-2784847793"},"reference-count":150,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody\u2013drug conjugates (ADCs) have emerged as a promising therapeutic class in the treatment of gynecologic malignancies, offering a targeted therapy approach that links tumor specific monoclonal antibodies with cytotoxic payloads. By selectively delivering chemotherapy to tumor cells expressing specific antigens, ADCs aim to enhance efficacy while potentially minimizing off\u2010target toxicity. In recent years, several ADCs have entered clinical trials in ovarian, cervical, and endometrial cancers, with encouraging activity observed in tumors expressing targets such as folate\u2010receptor \u03b1, human epidermal growth factor receptor 2, and tissue factor. This review provides an overview of the ADC treatment landscape in gynecologic oncology, highlighting approved agents, key clinical trials, and emerging ADC candidates. The authors critically examine ongoing challenges in the development and clinical integration of ADCs, including sequencing strategies, the impact of type of payload (particularly topoisomerase\u2010I inhibitors and microtubule\u2010disrupting agents), tumor target expression, linker and drug\u2013antibody ratio characteristics on both the toxicity and therapeutic index. Additionally, the authors address potential mechanisms of resistance that may limit durability of response and impact potential treatment sequences. Future challenges include the potential for ADCs to serve as maintenance therapies, and the rationale for combination strategies with immunotherapy, antiangiogenics, chemotherapy or targeted agents. As the understanding of ADC pharmacology deepens, these agents will play an increasingly central role in the rapidly evolving treatment paradigm of gynecologic cancers.<\/jats:p>","DOI":"10.1002\/cncr.70417","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:44:33Z","timestamp":1780371873000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antibody\u2013drug conjugates in gynecologic cancers"],"prefix":"10.1002","volume":"132","author":[{"given":"Arantzazu","family":"Barquin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Centro Integral Oncol\u00f3gico Clara Campal  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Kasherman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Illawarra Cancer Care Centre  Wollongong New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-5890","authenticated-orcid":false,"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital Cancer Centre, Medical Oncology and Haematology  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[{"name":"Medical Oncology Department 12 de Octubre University Hospital  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113350"},{"key":"e_1_2_8_4_1","unstructured":"Surveillance Epidemiology and End Results Program.Cervical Cancer\u2014Cancer Stat Facts. Accessed July 1 2025.https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html"},{"key":"e_1_2_8_5_1","unstructured":"Surveillance Epidemiology and End Results Program.Uterine Cancer\u2014Cancer Stat Facts. Accessed July 1 2025.https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810858"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910962"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911361"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00914"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.006"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc\u20102022\u2010003727"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01771"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100579"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.6004\/JADPRO.2022.13.1.4"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201024\u20100708"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2309169"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2313811"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201000947\u20107"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0B013E3182774562"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.713583"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0191972"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.5283"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.5858\/ARPA.2020\u20100207\u2010RA"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.12.019"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJOG.2011.06.093"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0B013E318228F6DA"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10585\u2010011\u20109401\u20100"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3892\/ETM.2018.6723"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102489"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198310133091503"},{"issue":"2","key":"e_1_2_8_31_1","first-page":"S544","article-title":"Claudin\u20106 expression in primary and recurrent epithelial ovarian cancer: a potential therapeutic target for high\u2010grade serous ovarian cancer","volume":"35","author":"Shintani D","year":"2024","journal-title":"Ann Oncol"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090\u20108258(22)01432\u20109"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010022\u201005161\u20105"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2014.03.553"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/MODPATHOL.2010.95"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41417\u2010022\u201000575\u2010X"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS222212443"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.12200"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.18007"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.07.015"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31774\u2010X"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/BJC.2017.367"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.042"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8CS00676H"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.BIOCONJCHEM.6B00337"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOCHI.2024.09.001"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14020396"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.MCR\u201019\u20100582"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.06.015"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS14081707"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRC1317"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41571\u2010021\u201000470\u20108"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201004\u20100789"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.BIOCONJCHEM.7B00062"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJZ035"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000476"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20100991\/726690\/AM\/FDA\u2010APPROVAL\u2010SUMMARY\u2010MIRVETUXIMAB\u2010SORAVTANSINE"},{"key":"e_1_2_8_59_1","unstructured":"European Medicines Agency.Elahere. Accessed July 1 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elahere"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2024.11.008"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2024.11.010"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2017.08.015"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.011"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_SUPPL.TPS5637"},{"key":"e_1_2_8_65_1","unstructured":"ConroyS.Rina\u2010S elicits encouraging antitumor activity in advanced ovarian cancer. Accessed July 1 2025.https:\/\/www.cancernetwork.com\/view\/rina\u2010s\u2010elicits\u2010encouraging\u2010antitumor\u2010activity\u2010in\u2010advanced\u2010ovarian\u2010cancer"},{"issue":"2","key":"e_1_2_8_66_1","first-page":"S718","article-title":"First\u2010in\u2010human study of AZD5335, a folate receptor \u03b1 (FR\u03b1)\u2010targeted antibody\u2010drug conjugate, in patients with platinum\u2010resistant recurrent ovarian cancer","volume":"36","author":"Oaknin A","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"e_1_2_8_67_1","first-page":"S718","article-title":"Results from the first\u2010in\u2010human phase I study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha in recurrent platinum resistant high\u2010grade serous ovarian cancer (HGSOC)","volume":"36","author":"Ray\u2010Coquard IL","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_SUPPL.5513"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3023"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.5517"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"e_1_2_8_72_1","unstructured":"Food and Drug Administration.FDA grants accelerated approval to fam\u2010trastuzumab deruxtecan\u2010nxki for unresectable or metastatic HER2\u2010positive solid tumors. Accessed July 1 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010fam\u2010trastuzumab\u2010deruxtecan\u2010nxki\u2010unresectable\u2010or\u2010metastatic\u2010her2"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.5557"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.5565"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.5612"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2024.08.776"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.777"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1924"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.3042"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy023"},{"key":"e_1_2_8_81_1","unstructured":"FlahertyC.Journey ends for upifitamab rilsodotin in NaPi2b+ platinum\u2010resistant ovarian cancer. Accessed July 1 2025.https:\/\/www.onclive.com\/view\/journey\u2010ends\u2010for\u2010upifitamab\u2010rilsodotin\u2010in\u2010napi2b\u2010platinum\u2010resistant\u2010ovarian\u2010cancer"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw401"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1136\/IJGC\u20102024\u2010IGCS.73"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201020\u20103757"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201024\u20103128"},{"issue":"2","key":"e_1_2_8_86_1","first-page":"S718","article-title":"Biparatopic anti\u2010HER2 antibody drug conjugate (ADC) JSKN003 in the treatment of primary platinum\u2010refractory ovarian cancer (OC)","volume":"36","author":"Li J","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_8_87_1","unstructured":"MooreV.Raludotatug deruxtecan shows efficacy in previously treated ovarian cancer. Accessed September 20 2025.https:\/\/www.cancertherapyadvisor.com\/reports\/raludotatug\u2010deruxtecan\u2010efficacy\u2010previously\u2010treated\u2010ovarian\u2010cancer\/"},{"issue":"2","key":"e_1_2_8_88_1","first-page":"S1","article-title":"Raludotatug deruxtecan (R\u2010DXd) in patients (pts) with platinum\u2010resistant ovarian cancer (PROC): primary analysis of the phase II dose\u2010optimization part of REJOICE\u2010Ovarian01","volume":"36","author":"Ray\u2010Coquard IL","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"e_1_2_8_89_1","first-page":"S1","article-title":"NAPISTAR 1\u201001: a phase I dose escalation study of TUB\u2010040, a novel NaPi2b\u2010targeting exatecan antibody\u2010drug conjugate (ADC) in patients with platinum\u2010resistant ovarian (PROC) high grade serous carcinoma (HGSC)","volume":"36","author":"Gonz\u00e1lez\u2010Mart\u00edn A","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"e_1_2_8_90_1","first-page":"S718","article-title":"Claudin\u2010 6 (CLDN6) is a therapeutic target in ovarian cancer (OC): emerging results from the CATALINA 1 (CAT1) study","volume":"36","author":"Wahner Hendrickson AE","year":"2025","journal-title":"Ann Oncol"},{"issue":"36","key":"e_1_2_8_91_1","first-page":"S718","article-title":"HS\u201020089 in patients with platinum\u2010resistant ovarian cancer: results from an open\u2010label, multi\u2010center, phase 2 study","author":"Yuan G","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_8_92_1","unstructured":"Food and Drug Administration.FDA approves tisotumab vedotin\u2010tftv for recurrent or metastatic cervical cancer. Accessed July 1 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010tisotumab\u2010vedotin\u2010tftv\u2010recurrent\u2010or\u2010metastatic\u2010cervical\u2010cancer"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2024.07.038"},{"issue":"2","key":"e_1_2_8_94_1","first-page":"S718","article-title":"Efficacy and safety of sacituzumab tirumotecan (Sac\u2010TMT) monotherapy in advanced\/metastatic cervical cancer: results from a phase I\/II study (MK\u20102870\u2010001\/KL264\u201001)","volume":"36","author":"Yang Z","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2024.08.778"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc\u20102023\u2010ESGO.14"},{"key":"e_1_2_8_97_1","unstructured":"BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody\u2010Drug Conjugate Candidate BNT323\/DB\u20101303 in Endometrial Cancer. Accessed July 1 2025.https:\/\/investors.biontech.de\/news\u2010releases\/news\u2010release\u2010details\/biontech\u2010and\u2010dualitybio\u2010receive\u2010fda\u2010breakthrough\u2010therapy\/"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16322-5"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02767"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.23155"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1920"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.3039"},{"issue":"2","key":"e_1_2_8_103_1","first-page":"S718","article-title":"Rinatabart sesutecan (Rina\u2010S) for patients with advanced or recurrent endometrial cancer (a\/r EC): update from dose expansion cohort B2 of RAINFOL\u201001","volume":"36","author":"Cloven N","year":"2025","journal-title":"Ann Oncol"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10637\u2010017\u20100520\u20106"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJGC.2025.102117"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS17142307"},{"key":"e_1_2_8_108_1","doi-asserted-by":"publisher","DOI":"10.1089\/JOP.2023.0069"},{"key":"e_1_2_8_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155"},{"key":"e_1_2_8_110_1","first-page":"63","article-title":"Tissue factor expression in human pterygium","volume":"17","author":"Ando R","year":"2011","journal-title":"Mol Vis"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae177"},{"key":"e_1_2_8_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.23.00097"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404"},{"key":"e_1_2_8_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102043"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2024.101486"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241299935"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2449991"},{"key":"e_1_2_8_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11596\u2010025\u201000030\u20106"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ISCI.2023.107778"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101997"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2025.03.013"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201014\u20100862\/86497\/AM\/TUMOR\u2010CELLS\u2010CHRONICALLY\u2010TREATED\u2010WITH\u2010A\u2010TRASTUZUMAB"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1093\/JNCI\/DJK134"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201017\u20100403"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201016\u20103127"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/CAC2.12387"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1177\/23523735251317865"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2023.01.003"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15030713"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1093\/ONCOLO\/OYAE055"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41523\u2010025\u201000748\u20105"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.SABCS23\u2010PS08\u201003"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S46887"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJGC.2025.102906"},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.114932"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.37349\/ETAT.2024.00243"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2312117"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1111\/ECI.70001"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS17060958"},{"key":"e_1_2_8_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41571\u2010023\u201000850\u20102"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2276873"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJMECH.2024.116995"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3114"},{"key":"e_1_2_8_144_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162"},{"key":"e_1_2_8_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.01.009"},{"key":"e_1_2_8_146_1","doi-asserted-by":"publisher","DOI":"10.1186\/S13045\u2010023\u201001509\u20102"},{"key":"e_1_2_8_147_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00720"},{"key":"e_1_2_8_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/NSMB.2258"},{"key":"e_1_2_8_149_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201016\u20102401"},{"key":"e_1_2_8_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"e_1_2_8_151_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_SUPPL.E17580"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:51:31Z","timestamp":1780411891000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":150,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1002\/cncr.70417"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70417","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2025-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70417"}}